Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Online ISSN 1827-1820
Spandonaro F. 1, Altomare G. 2,3, Berardesca E. 4, Calzavara-Pinton P. 5, Chimenti S. 6, Girolomoni G. 7, Peserico A. 8, Puglisi Guerra A. 9, Vena G. A. 10, Polistena B. 1, Ayala F. 11
1 CEIS, University of Rome Tor Vergata, Rome, Italy
2 Department of Dermatology, University of Milan, Milan, Italy
3 Department of Dermatology, Galeazzi Hospital, Milan, Italy
4 Istituto Dermatologico S. Maria e S. Gallicano, Rome, Italy
5 Department of Dermatology, Spedali Civili of Brescia, Brescia, Italy
6 Department of Dermatology, University of Rome Tor Vergata, Rome, Italy
7 Department of Dermatology, University of Verona, Verona, Italy
8 Department of Dermatology, University of Padua, Padua, Italy
9 Department of Dermatology, Messina Hospital, Messina, Italy
10 Department of Dermatology, University of Bari, Bari, Italy
11 Department of Dermatology, University of Naples Federico II, Naples, Italy
AIM: Psoriasis is a common, chronic, immune-mediated skin disorder that may be complicated by psoriatic arthritis in up to one-third of patients. Psoriasis treatments are increasingly effective, yet more expensive, thus requiring rational decision-making on interventional priorities. The ability to perform cost-utility analyses is hindered by the lack of algorithms that allow the inference of utility measures, like QALY, from specific dermatological health-related quality-of-life (HR-QoL) measures (e.g. Dermatology Life Quality Index [DLQI]). This study aimed to assess whether psoriasis-related HR-QoL data (DLQI) could be used to obtain utility measures for use in economic analyses.
METHODS: Psoriasis patients attending 11 Italian Psocare project treatment centers over a 19-day period were enrolled and completed a questionnaire, including several HR-QoL scales and sociodemographic/clinical data, and underwent a clinical examination. Data were subjected to a Multiple Correspondence Analysis and multiple regression analysis to determine the contribution of single items to the HR-QoL.
RESULTS: DLQI and Psychological General Well-Being Index (PGWBI) scores were most closely correlated with the EuroQol health status index. Age and gender were considered confounding factors, while pain and arthritis contributed significantly to HR-QoL deterioration. For disease severity, the need for hospitalization and the number of examinations, but not the Psoriasis Area Severity Index (PASI), contributed to HR-QoL deterioration.
CONCLUSION: Recent historical clinical and HR-QoL data from psoriasis patients can reproducibly define a health status index, such as the EuroQol SD-5Q, that could be used reliably to estimate QALYs for use in cost-utility analyses to compare the cost-benefit profiles of competing therapies.